Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.

Goal 2: Reduce Human Disease

Optimize vaccine responses in HCT recipients and patients with hematologic malignancies

Vaccination responses are poor early after hematopoietic cell transplantation and in the context of cytotoxic chemotherapy. To design effective vaccination strategies it is critical to understand the immune correlates of protection. There is a need to study strategies to study and improve vaccine efficacy in this growing population of immunosuppressed individuals that is increasingly of advanced age.

Submitted by (@mboeckh)

Voting

15 net votes
25 up votes
10 down votes
Active

Goal 2: Reduce Human Disease

Palliation of symptoms associated with pulmonary conditions; promotion of patient participation in symptom self-management

Palliation of symptoms associated with a number of pulmonary conditions; promotion of patient participation in symptom self-management across the spectrum of illness, from ICU admission to rehabilitation to home; requires a multi-disciplinary perspective and team. There are a plethora of distressing symptoms (anxiety, shortness of breath, cough, fatigue, weakness) associated with a number of chronic pulmonary conditions, ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Treatment of Major Depression in Patients with Heart Failure

Major depression (MD) is common in patients with heart failure, and it is an independent risk marker for functional decline, hospitalization, and mortality. Two large trials have shown that it can be difficult to treat. SADHART-CHF, a double-blind, placebo-controlled RCT (n=469), found that sertraline was not efficacious for MD in HF. MOOD-HF (n=372) showed that escitalopram was not efficacious. Smaller trials of cognitive-behavioral ...more »

Submitted by (@freedlak)

Voting

8 net votes
27 up votes
19 down votes
Active

Goal 2: Reduce Human Disease

Understanding Pathobiology of Exacerbations

COPD exacerbations contribute to poor quality of life, lung function and functional decline. In addition, they are costly to the patient and to health care cost. However, they remain defined exclusively on symptoms and constitute a “soft” endpoint. Actually, the number of exacerbations has become the GOLD standard to establish the risk of outcome (exacerbations). However, a mild episode that only requires outpatient ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Innovations in Red Cell Transfusion in Sickle Cell Disease

Challenges that need to be overcome in blood transfusion, especially in SCD, include: a. Adopting molecular genotyping as the standard in blood transfusion therapy. b. Advancing new generation, anti-oxidant hemoglobin-based oxygen carriers (HBOCs) for use in emergencies such as trauma, stroke, acute hemolysis, and in transfusion in SCD and related disorders. In SCD, HBOCs have the capacity to not only serve as substitutes ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

29 net votes
47 up votes
18 down votes
Active

Goal 2: Reduce Human Disease

Hormonal influences on atherosclerotic cardiovascular disease (ASCVD)

Cardiovascular diseases are the leading cause of morbidity and mortality for both men and women worldwide. It has been established that post-menopausal women have decreased protection from ASCVD relative to premenopausal women and men. However, the hormonal basis of protection (or lack thereof) is not clear.

Submitted by (@jlaakso)

Voting

2 net votes
6 up votes
4 down votes
Active

Goal 2: Reduce Human Disease

Reducing Disparities

Given the dearth of information on cardiovascular, lung, and hematologic outcomes in minorities, NHLBI should develop strategic aims that promote evaluation of these outcomes and potential interactions with kidney disease that disproportionately affect minorities.

Submitted by (@golan0)

Voting

0 net votes
1 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

mechansisms of post thrombotic syndrome

No good medical therapy exists to prevent and treat post thrombotic syndrome, the most common sequlae from a deep vein thrombosis. Recent trial data suggests that compression stockings do not prevent PTS, and thrombolysis is expensive and risky. The basic mechanisms related to fibrosis of the vein wall are not well understood.

Submitted by (@henke0)

Voting

1 net vote
5 up votes
4 down votes
Active